Cadrenal Therapeutics Inc (CVKD)
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on therapies for rare cardiovascular conditions. Its lead program is Tecarfarin, an oral and reversible anticoagulant under development to help prevent heart attacks, strokes, and blood-clot-related deaths in patients who require long-term anticoagulation, including those with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic antiphospholipid syndrome. The company also has a collaboration agreement with Abbott Global Enterprises Limited to assess the safety and efficacy of Tecarfarin in patients with a left ventricular assist device. Cadrenal Therapeutics was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. The company’s common stock trades on the NASDAQ under the symbol CVKD.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CVKD
|
$1.35
|
25.8% Upside
|
Undervalued
|
$14 1,208.4% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
November 5, 2026
|
0.9x
|
3.817 M
|
1.429 M
|
0.0%
|
88.1%
|
-15.6
|
88.1%
|
